Panelists discuss the importance of effective communication and multidisciplinary collaboration in managing immunotherapy toxicities and ensuring seamless patient care, while highlighting promising advances in melanoma treatment and the role of telehealth and community outreach in expanding access and improving outcomes.
Panelists discuss the complexities of managing metastatic melanoma with asymptomatic brain metastases in patients with good performance status, emphasizing challenges posed by treatment resistance and highlighting emerging therapies—such as genetically modified T cells, bispecific T-cell engagers, and intralesional oncolytic viruses—that aim to improve durable outcomes in advanced disease.
This is an actor portrayal of a hypothetical patient profile developed for educational purposes based on characteristics of patients with multiple myeloma as seen in clinical practice. The hypothetical case was co-developed by staff Medical Writers with Cancer Network/ONN.
Panelists discuss the critical role of patient education and multidisciplinary coordination in managing immunotherapy side effects, emphasizing proactive symptom monitoring, timely communication, tailored support, and collaborative care led by the oncologist to ensure safe and effective toxicity management.
Panelists discuss the importance of vigilant, patient-centered monitoring for metastatic melanoma patients with high disease burden on immunotherapy, emphasizing clear communication about variable treatment responses, proactive symptom tracking, differentiation of true progression from pseudoprogression, and integration of clinical assessments with biomarkers like lactate dehydrogenase and circulating tumor DNA to guide optimal care.
This is an actor portrayal of a hypothetical patient profile developed for educational purposes based on characteristics of patients with multiple myeloma as seen in clinical practice. The hypothetical case was co-developed by staff medical writers with Cancer Network/ONN.
Panelists discuss treatment considerations for metastatic melanoma with high tumor burden, highlighting the preference for immune checkpoint combinations like nivolumab with relatlimab for durable responses, insights from the RELATIVITY-020 trial supporting standard-dose relatlimab due to its safety and efficacy balance, and emerging LAG-3 agents such as fianlimab that may influence future therapeutic strategies.
